News about Clinical Trials

Sun Pharma Advanced Research announces positive results from phase 3 trial of PDP-716 to treat open angle glaucoma

Sun Pharma Advanced Research Company Ltd. (SPARC) reported positive top-line results from its phase 3 trial (CLR_16_33) for its investigational drug, PDP-716 ophthalmic suspension, for the treatment of open angle glaucoma or ocular hypertension

Clinical Trials | 14/05/2021 | By Darshana |  325

CNS Pharma completes manufacturing strategy for Berubicin to treat glioma brain tumors

CNS Pharmaceuticals, a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and CNS, provided an update on the manufacturing strategy for Berubicin drug product, its lead drug candidate for the treatment of glioma brain tumors

Clinical Trials | 17/07/2020 | By Darshana |  643

China to run human coronavirus vaccine trial in UAE

China National Biotec Group (CNBG) has won approval to run a large-scale Phase 3 clinical trial of its novel coronavirus vaccine candidate in the United Arab Emirates (UAE), the company said. China is seeking to trial potential vaccines overseas because of a lack of new patients at home

Clinical Trials | 25/06/2020 | By Darshana |  457

Roche's IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints

Roche today announced that the phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) and whose tumours had PTEN loss

Clinical Trials | 19/06/2020 | By Darshana |  417

FDA Issues Warning Letters to Companies Inappropriately Marketing Antibody Tests, Potentially Placing Public Health at Risk

The U.S. Food and Drug Administration has issued warning letters to three companies for marketing adulterated and misbranded COVID-19 antibody test

Clinical Trials | 18/06/2020 | By Darshana |  451

Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia

Roche announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc

Clinical Trials | 28/05/2020 | By Darshana |  570

FDA Approves First Therapy for Patients with Lung and Thyroid Cancers with a Certain Genetic Mutation or Fusion

Today, the U.S. Food and Drug Administration approved Retevmo (selpercatinib) capsules to treat three types of tumors non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers in patients whose tumors have an alteration (mutation or fusion) in a specific gene

Clinical Trials | 10/05/2020 | By Darshana |  317

ICMR announces protocol for Therapeutic Plasma Exchange therapy in COVID-19 patients

The Indian Council of Medical Research (ICMR) has announced protocol for a multi-center, phase II, open label, randomized controlled study named Therapeutic Plasma Exchange (TPE) in COVID-19 for its therapy. The therapy is also called convalescent plasma therapy which according to health experts has the potential to treat critically ill COVID-19 patient

Clinical Trials | 15/04/2020 | By Darshana |  330

Roche provides regulatory update on risdiplam for the treatment of spinal muscular atrophy (SMA)

Roche, announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the New Drug Application (NDA) of risdiplam with a decision expected by August 24, 2020

Clinical Trials | 13/04/2020 | By Darshana |  381

First patient outside U.S. treated in global Kevzara clinical trial program for patients with severe COVID-19

The first patient outside of the U.S. has been treated as part of a global clinical program evaluating Kevzara in patients hospitalized with severe COVID-19. The global clinical program has now been initiated in Italy, Spain, Germany, France, Canada, Russia and the United States, all countries that have been impacted by COVID-19

Clinical Trials | 30/03/2020 | By Darshana |  308